{"name":"Arpida AG","slug":"arpida-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Intravenous iclaprim","genericName":"Intravenous iclaprim","slug":"intravenous-iclaprim","indication":"Complicated skin and soft tissue infections (cSSTI)","status":"phase_3"},{"name":"Intravenous linezolid","genericName":"Intravenous linezolid","slug":"intravenous-linezolid","indication":"Gram-positive bacterial infections including MRSA and VRE","status":"phase_3"},{"name":"intravenous iclaprim or intravenous linezolid","genericName":"intravenous iclaprim or intravenous linezolid","slug":"intravenous-iclaprim-or-intravenous-linezolid","indication":"Complicated skin and skin structure infections","status":"phase_3"}]}],"pipeline":[{"name":"Intravenous iclaprim","genericName":"Intravenous iclaprim","slug":"intravenous-iclaprim","phase":"phase_3","mechanism":"Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that disrupts bacterial folate metabolism, preventing DNA synthesis and bacterial growth.","indications":["Complicated skin and soft tissue infections (cSSTI)","Hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP)"],"catalyst":""},{"name":"Intravenous linezolid","genericName":"Intravenous linezolid","slug":"intravenous-linezolid","phase":"phase_3","mechanism":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","indications":["Gram-positive bacterial infections including MRSA and VRE","Nosocomial pneumonia","Complicated skin and soft tissue infections","Community-acquired pneumonia"],"catalyst":""},{"name":"intravenous iclaprim or intravenous linezolid","genericName":"intravenous iclaprim or intravenous linezolid","slug":"intravenous-iclaprim-or-intravenous-linezolid","phase":"phase_3","mechanism":"Iclaprim inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.","indications":["Complicated skin and skin structure infections","Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}